Abbott Laboratories (ABT.N)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|62||1999||Chairman of the Board, Chief Executive Officer|
|47||2015||Chief Financial Officer, Senior Vice President - Finance|
|61||2017||President - Cardiovascular and Neuromodulation|
|51||2013||Executive Vice President, General Counsel, Secretary|
|59||2013||Executive Vice President - Human Resources|
- BRIEF-Alere announces intent to voluntarily delist Series B Convertible Perpetual Preferred Stock from the NYSE
- BRIEF-Abbott announces extension of cash tender offer
- BRIEF-Abbott sets quarterly dividend of $0.265 per share
- BRIEF-Abbott Laboratories says NHS Business Services Authority approved listing on Drug Tariff for FreeStyle Libre system
- BRIEF-Abbott extends cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere